Vesselon Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $625K
Latest Deal Amount
  • Investors
  • 2

Vesselon General Information

Description

Developer of immuno-oncology therapies designed to be protected in circulation and actively targeted to tumors using an FDA-approved lipid microsphere drug. The company's therapies are formed at the time of administration (rather than at the drug manufacturing stage), allowing the creation of new complexes from already approved therapeutics, enabling doctors to treat a wide spectrum of cancers and other series of diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Drug Discovery
Drug Delivery
Primary Office
  • 101 Merritt 7
  • Suite 300
  • Norwalk, CT 06851
  • United States
+1 (203) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vesselon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 19-Aug-2016 $625K 000 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 11-Jun-2015 000 000 00.00 Completed Pre-Clinical Trials
1. Seed Round 01-Jan-2014 Completed Startup
To view Vesselon’s complete valuation and funding history, request access »

Vesselon Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00 00 00 00.000
To view Vesselon’s complete cap table history, request access »

Vesselon Patents

Vesselon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2017538545-A Automatic ultrasound non-invasive revascularization treatment and monitoring apparatus and method Pending 15-Dec-2014 00000000
US-20180001114-A1 Automated ultrasound apparatus and method for noninvasive vessel recanalization treatment and monitoring Abandoned 15-Dec-2014 00000000 0

Vesselon Executive Team (3)

Name Title Board Seat Contact Info
Clayton Larsen Co-Founder, President & Chief Executive Officer
Neil Edwards Chief Financial Officer
Rhodemann Li Co-Founder & Executive Vice President,of Finance & Strategy
To view Vesselon’s complete executive team members history, request access »

Vesselon Board Members (8)

Name Representing Role Since
Adam Levy Ph.D Vesselon Board Member 000 0000
James Galeota Jr. Self Board Member 000 0000
Jon Serbousek Self Chairman 000 0000
Jürgen Raths MD Vesselon Board Member 000 0000
Kevin Kimberlin Spencer Trask & Co. Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Vesselon Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vesselon Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Connecticut Innovations Venture Capital Minority 000 0000 000000 0
Spencer Trask & Co. Venture Capital Minority 000 0000 000000 0
To view Vesselon’s complete investors history, request access »